ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print
COVID vaccines

Japan's 1st plant for mRNA COVID vaccine to be built by Daiichi Sankyo

Drugmaker targets capacity of 20m doses yearly, boosting nation's preparedness

A health care worker administers a vaccine in Osaka. Japan is pivoting away from treating COVID-19 as a health emergency. (Photo by Arisa Moriyama)

TOKYO -- Drugmaker Daiichi Sankyo is building the first factory in Japan for a homegrown mRNA vaccine against COVID-19, with a planned capacity of 20 million doses a year by fiscal 2024, Nikkei has learned.

Production equipment has been installed at a plant run by subsidiary Daiichi Sankyo Biotech, based near Tokyo in Kitamoto. Daiichi Sankyo in January filed for approval of its COVID-19 vaccine candidate, now in development.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more